You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 114 Preclinical development of a novel iPSC-derived CAR-MICA/B NK cell immunotherapy to overcome solid tumor escape from NKG2D-mediated mechanisms of recognition and killing

Citation Tools

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Cellular therapies
114 Preclinical development of a novel iPSC-derived CAR-MICA/B NK cell immunotherapy to overcome solid tumor escape from NKG2D-mediated mechanisms of recognition and killing

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Goulding J, Pribadi M, Blum R, et al
114 Preclinical development of a novel iPSC-derived CAR-MICA/B NK cell immunotherapy to overcome solid tumor escape from NKG2D-mediated mechanisms of recognition and killing
Journal for ImmunoTherapy of Cancer 2020;8:doi: 10.1136/jitc-2020-SITC2020.0114